Obesity Doppler in Term Pregnancy

The Effect of Maternal Obesity on Umbilical and Uterine Artery Doppler in Term Pregnancy : a Cross-sectional Study

Maternal obesity is an epidemic in the developed world like Egypt. There are many pregnancy-associated complications including pre-eclampsia, gestational diabetes, and increased rates of septic wound after cesarean delivery. As a potential explanation of the etiology of complications due to maternal obesity, the role of endothelial dysfunction in the systemic and peripheral vasculatures has been hypothesized. It has been proposed that some adverse pregnancy outcomes in obese patients may be mediated by placental insufficiency. Utero-placental insufficiency is typically associated with fetal growth restriction and low birth weight.

Umbilical and uterine artery Doppler is widely accepted as a useful tool for monitoring high-risk pregnancies.

Normally, uterine artery vascular impedance gradually decreases until the late mid-trimester, owing to the establishment of a low-resistance placental circulation. Obesity has little impact on uterine vascular changes reflected by the early uterine artery PI. However, in the second trimester, extreme obesity appears to impair the normal continued drop in uterine vascular resistance. Many studies have examined the relationship between BMI and Doppler changes in high-risk pregnancies, but few have addressed these changes in low-risk pregnancies.

Study Overview

• Status: Recruiting
• Conditions: Doppler Measurement of Uterine Artery

• Study Type: Observational
• Enrollment (Estimated): 240

Contacts and Locations

• Study Contact: Name: Mohammed Khairy Ali, MD; Phone Number: 01005537951; Email: mohammedelkosy@aun.edu.eg

Study Locations

• Egypt
  • Assiut, Egypt, 71111
    • Recruiting
    • Woman's Health Hospital - Assiut university
    • Contact: Mohammed K ALi, MD; Phone Number: +201005537951; Email: m_khairy2001@yahoo.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Pregnant women

Description

Inclusion Criteria:

1. Singleton pregnancy
2. Gestational age ≥ 37 weeks
3. Absence of fetal structural abnormalities
4. Absence of maternal comorbidities and/or complications.
5. Obese women (BMI ≥ 30 kg/m2) [11].
6. Normal weight (BMI 18.5-24.9) [11].

Exclusion Criteria:

1. Placenta previa
2. Women with antepartum hemorrhage.
3. Smokers and alcohol consumers
4. Preeclampsia
5. Diabetes mellitus
6. Women need urgent termination of pregnancy.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Normal weight pregnant women; Normal weight (body mass index 18.5-24.9 kg/m2)
Obese pregnant women; women (body mass index ≥ 30 kg/m2)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The difference between uterine and umbilical artery Doppler resistant index	The difference between uterine and umbilical artery Doppler indices between normal weight and obese pregnant women ≥ 37 weeks.	at 37 weeks of pregnancy

Collaborators and Investigators

• Sponsor: Assiut University

Study record dates

Study Major Dates

• Study Start (Actual): January 20, 2025
• Primary Completion (Estimated): January 1, 2026
• Study Completion (Estimated): January 1, 2026

Study Registration Dates

• First Submitted: October 15, 2024
• First Submitted That Met QC Criteria: October 15, 2024
• First Posted (Actual): October 16, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 24, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Body Weight; Overweight; Obesity
• Other Study ID Numbers: Doppler-150

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No